Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.42
Nov 19 • 3:30 PM ET Dollar change+0.57 Percentage change(66.61%)
Today, 7:06 AMMarker Therapeutics won a $16.2 million CPRIT grant to support Phase 2 development of MT-601 in its APOLLO lymphoma study.
Index
-
Market Cap
23.71M
Enterprise Value
14.28M
Income
-8.55M
Sales
1.10M
Book/sh
0.63
Cash/sh
0.57
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
5
IPO
Jan 05, 1998
P/E
-
Forward P/E
-
PEG
-
P/S
21.55
P/B
2.26
P/C
2.51
P/FCF
-
EV/EBITDA
-
EV/Sales
12.98
Quick Ratio
6.26
Current Ratio
6.26
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-0.46
EPS next Y
-0.76
EPS next Q
-0.20
EPS this Y
30.80%
EPS next Y
-39.63%
EPS next 5Y
-
EPS past 3/5Y
39.48% 33.49%
Sales past 3/5Y
0.31% 50.02%
EPS Y/Y TTM
62.83%
Sales Y/Y TTM
-76.50%
EPS Q/Q
19.95%
Sales Q/Q
-100.00%
Insider Own
19.03%
Insider Trans
0.00%
Inst Own
10.40%
Inst Trans
-0.02%
ROA
-49.97%
ROE
-59.21%
ROIC
-81.44%
Gross Margin
-
Oper. Margin
-1069.94%
Profit Margin
-775.14%
SMA20
48.92%
SMA50
37.07%
SMA200
8.89%
Trades
Shs Outstand
16.67M
Shs Float
13.50M
52W High
2.46 -42.22%
52W Low
0.81 75.47%
Volatility
9.49% 11.32%
ATR (14)
0.15
RSI (14)
70.51
Beta
1.64
Rel Volume
296.66
Avg Volume
123.36K
Volume
33,920,978
Perf Week
57.94%
Perf Month
25.80%
Perf Quarter
2.27%
Perf Half Y
-0.59%
Perf YTD
-4.60%
Perf Year
30.41%
Perf 3Y
-50.12%
Perf 5Y
-89.07%
Perf 10Y
-96.88%
Prev Close
0.85
Price
1.42
Change %
66.61%
Consensus
Strong Buy
Avg. Price Target
$7.87
Implied Upside
+453.6%
Analysts6incl. previous ratings
Rating Distribution6 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Mar 05, 2025Initiated
CCanaccord Genuity
Buy$8+462.8%
Mar 25, 2021Initiated
PPiper Sandler
Overweight$6+322.1%
Mar 19, 2021Initiated
CCantor Fitzgerald
Overweight$6+322.1%
May 12, 2020Downgrade
PPiper Sandler
Overweight → Neutral$5 → $2.50+75.9%
May 30, 2019Initiated
RROTH Capital
Buy
Mar 01, 2019Initiated
JJanney
Buy
Dec 03, 2018Upgrade
PPiper Jaffray
Neutral → Overweight
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
Co-FounderDr. Juan F. Vera M.D.
Director of AdministrationMs. Elizabeth Donnelly
Director of Corporate Operations & External CommunicationsDr. Maria-Bernadette Madel Ph.D.
Vice President of Human ResourcesMr. Edmund Cheung
Head of Clinical OperationsPatricia Allison